Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: A meta-analysis and systematic review

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1593-1599

  He, Xuepeng ^a   Yang, Kai ^a   Chen, Peng ^a   Liu, Bing ^a   Zhang, Yuan ^a   Wang, Fang ^a   Guo, Zhi ^a   Liu, Xiaodong ^a   Lou, Jinxing ^a   Chen, Huiren ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Arsenic trioxide; Clinical trial; Meta analysis; Multiple myeloma; Therapy

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ANEMIA; ARTICLE; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEART DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DISEASE; META ANALYSIS; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 84907194011     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S67165     Document Type: Article

References (49)

1. Rollig C, Illmer T. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat Rev. 2009;35:425–430.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
3. Genadieva-Stavric S, Cavallo F, Palumbo A. New approaches to management of multiple myeloma. Curr Treat Options Oncol. 2014; 15(2):157–170.
4. Dalton WS. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: Bahlis NJ, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/ refractory multiple myeloma. Clin Cancer Res. 2002;8:3658–3668.
5. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol. 1998;177:324–333.
6. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000;14:262–270.
7. Jia P, Chen G, Huang X, et al. Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3. Chin Med J (Engl). 2001; 114:19–24.
8. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345–3353.
9. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354–3360.
10. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60:3065–3071.
11. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639–16647.
12. Matulis SM, Morales AA, Yehiayan L, Lee K P, Cai Y, Boise LH. Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. PLoS One. 2012;7:e52662.
13. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115–1123.
14. Hofmeister CC, Jansak B, Denlinger N, Kraut EH, Benson DM, Farag SS. Phase II clinical trial of arsenic trioxide with liposomal doxo-rubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res. 2008;32:1295–1298.
15. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/ refractory multiple myeloma. Clin Cancer Res. 2002;8:3658–3668.
16. Berenson JR, Swift RA, Ferretti D, Purner MB. A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. Clin Lymphoma. 2004;5:130–134.
17. Borad MJ, Swift R, Berenson JR. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia. 2005;19:154–156.
18. Gesundheit B, Shapira MY, Resnick I, et al. Trisenox (arsenic trioxide) in the treatment for multiple myeloma after bone marrow transplantation. Blood. 2005;106:365B.
19. Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 2002;16:1835–1837.
20. Rousselot P, Larghero J, Arnulf B, et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia. 2004;18:1518–1521.
21. Held LA, Rizzieri D, Long GD, et al. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. Cancer Invest. 2013;31:172–176.
22. Sanaat Z, Rezazadeh M, Gharamaleki J V, Ziae JE, Esfahani A. Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. Acta Med Iran. 2011;49:504–508.
23. Dey S, Gupta P, Chitalkar PG, Mukhopadhyay A. Arsenic trioxide for treatment of multiple myeloma. Ann Oncol. 2007;18:9178–9182.
24. Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008;14:1401–1407.
25. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Ye h HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007;13:1762–1768.
26. Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006;135:174–183.
27. Abou-Jawde RM, Reed J, Kelly M, et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol. 2006;23:263–272.
28. Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica. 2006;91:1722–1723.
29. Rebersek K, Zontar DM, Cernelč P, Podgornik H. Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide. Hematology. 2014;19(6):346–351.
30. Yang D, Cao F, Ye X, et al. Arsenic trioxide inhibits the hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia. Acta Haematol. 2013;130:260–267.
31. Qu H, Tong D, Zhang Y, Kang K, Chen L, Ren L. The synergistic anti-tumor activity of arsenic trioxide and vitamin K2 in HL-60 cells involves increased ROS generation and regulation of the ROS-dependent MAPK signaling pathway. Pharmazie. 2013;68:839–845.
32. Cheng Y, Xue J, Jiang H, et al. Neuroprotective effect of resveratrol on arsenic trioxide-induced oxidative stress in feline brain. Hum Exp Toxicol. 2013;33(7):737–747.
33. Marchetti P, Mortier L, Beauvillain V, Formstecher P. Are mitochondria targets of anticancer drugs responsible for apoptosis?. Ann Biol Clin (Paris). 2002;60:391–403.French.
34. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–115.
35. Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 1998;58:256–262.
36. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91: 3–21.
37. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci. 2006;97:540–545.
38. Wen J, Feng Y, Huang W, et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res. 2010;34:85–92.
39. Wen J, Cheng HY, Feng Y, et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol. 2008;140:169–180.
40. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000;275: 36062–36066.
41. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428–435.
42. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991–6000.
43. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1:851–860.
44. Zhang WJL, Bao S. Arsenic trioxide-based treatment of relapsed and refractory multiple myeloma. Chinese Community Physician. 2012;14:124–125.
45. Yan JWB, Xue Z, Sun J, Song Z. Clinical efficiency of arsenic trioxide for the treatment of relapsed/refractory multiple myeloma. Journal of Clinical Hematology. 2004;17:207–208.
46. Sharma M, Khan H, Thall P F, et al. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012;118:2507–2515.
47. Karasavvas N, Carcamo JM, Stratis G, Golde DW. Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood. 2005;105: 4004–4012.
48. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2004;125:470–476.
49. Baz RC, Kelly M, Reed J, et al. Phase II study of dexamethasone, ascorbic acid, thalidomide and arsenic trioxide (DATA) in high risk previously untreated (PU) and relapsed/refractory (RR) multiple myeloma (MM). J Clin Oncol. 2006;24:17535.